BioSpace News Archive

RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, announced plans to participate in the upcoming Wells Fargo Healthcare Conference.

The National Resident Matching Program® is pleased to announce the return of its national in-person stakeholder conference, Transition to Residency, on October 6 – 8, 2022 on Coronado Island near San Diego, CA.

Dermata Therapeutics, Inc., a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announced that Dermata will participate in the Gilmartin Group Emerging Growth Company Showcase, being held on August 31, 2022.

Children’s Hospital New Orleans and Cleveland Clinic are pleased to announce a new affiliation to expand access to board-certified pediatric radiology experts for children and families of New Orleans and Louisiana.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 2022 Healthcare Conference on Wednesday, September 7, 2022 at 12:30pm Eastern Time.

Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, will report financial results for the six months ending June 30, 2022, on Thursday, August 25, 2022 at approximately 4:00 p.m. Eastern Time.

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2022 fourth quarter and full year ended June 30, 2022.

Linamar Corporation (TSX: LNR), a leading global diversified manufacturing company, announced today its iHub production site has received ISO 13485 certification for medical device production.

Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended June 30, 2022.

Alpha Biopharma, a developer of innovative drugs, announces the completion of last patient last visit (LPLV) in its international, multicenter EVEREST phase II/III clinical study of Zorifertinib, a next-generation EGFR-TKI, in first line patients with advanced EGFRm+ non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases.